{
"id":"mk19_a_gm_t43",
"number":43,
"bookId":"gm",
"title":{
"__html":"Summary of the U.S. Department of Veterans Affairs/U.S. Department of Defense Dyslipidemia Pharmacotherapy Recommendations "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"441327",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 43. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t43"
}
]
},
"Summary of the U.S. Department of Veterans Affairs/U.S. Department of Defense Dyslipidemia Pharmacotherapy Recommendations "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8b2982",
"class":"col hd l",
"children":[
"Recommendation Topic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f8b79",
"class":"col hd l",
"children":[
"Conclusion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec5a0a",
"class":"col hd l",
"children":[
"Primary Prevention"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94793c",
"class":"cell txt l",
"children":[
"Moderate-intensity statin therapy for patients with a 10-year CVD risk ≥12%, an LDL cholesterol level ≥190 mg/dL (4.92 mmol/L), or diabetes mellitus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"654866",
"class":"cell txt l",
"children":[
"Recommended"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b56379",
"class":"cell txt l",
"children":[
"Moderate-intensity statin therapy for patients with a 10-year CVD risk between 6% and 12%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67bbc",
"class":"cell txt l",
"children":[
"Suggested"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"69f05e",
"class":"cell txt l",
"children":[
"PCSK9 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe8747",
"class":"cell txt l",
"children":[
"Recommended against"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"579bff",
"class":"cell txt l",
"children":[
"Ezetimibe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d85159",
"class":"cell txt l",
"children":[
"No recommendation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"84b94a",
"class":"col hd l",
"children":[
"Secondary Prevention"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4330a1",
"class":"cell txt l",
"children":[
"At least moderate-intensity statin therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"654866",
"class":"cell txt l",
"children":[
"Recommended"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ad6e2",
"class":"cell txt l",
"children":[
"High-intensity statin therapy for higher-risk patients",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67bbc",
"class":"cell txt l",
"children":[
"Suggested"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbb6eb",
"class":"cell txt l",
"children":[
"Adding ezetimibe to statin therapy for higher-risk patients",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67bbc",
"class":"cell txt l",
"children":[
"Suggested"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf079f",
"class":"cell txt l",
"children":[
"PCSK9 inhibitor for higher-risk patients",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b,c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67bbc",
"class":"cell txt l",
"children":[
"Suggested"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f00a7",
"class":"col hd l",
"children":[
"Other Medications, Supplements, and Nutraceuticals"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"594f92",
"class":"cell txt l",
"children":[
"Adding icosapent ethyl to statin therapy for secondary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67bbc",
"class":"cell txt l",
"children":[
"Suggested"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"82f783",
"class":"cell txt l",
"children":[
"Niacin for primary or secondary prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe8747",
"class":"cell txt l",
"children":[
"Recommended against"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"916f43",
"class":"cell txt l",
"children":[
"Adding fibrates to statin therapy for primary or secondary prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4294f",
"class":"cell txt l",
"children":[
"Suggested against"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64000f",
"class":"cell txt l",
"children":[
"Omega-3 fatty acids as dietary supplements for primary or secondary prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4294f",
"class":"cell txt l",
"children":[
"Suggested against"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f4969",
"class":"cell txt l",
"children":[
"Adding icosapent ethyl to statin therapy for primary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d85159",
"class":"cell txt l",
"children":[
"No recommendation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"423e55",
"class":"col hd l",
"children":[
"Monitoring"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b99869",
"class":"cell txt l",
"children":[
"Routine monitoring of lipid levels in patients receiving statin therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4294f",
"class":"cell txt l",
"children":[
"Suggested against"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CVD = cardiovascular disease; PCSK9 = proprotein convertase subtilisin/kexin type 9."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"In patients who are willing to intensify treatment after discussing the risk of high-intensity statin therapy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Higher-risk patients include those with a myocardial infarction or acute coronary syndrome in the past 12 months; recurrent acute coronary syndrome, myocardial infarction, or stroke; or established CVD with additional risk factors (e.g., currently smoking, diabetes, peripheral artery disease, or coronary revascularization)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"In patients who are willing to intensify treatment after discussing the uncertain long-term safety and benefits."
],
[
"Information from O’Malley PG, Arnold MJ, Kelley C, et al. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2020;173:822-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32956597",
"target":"_blank"
},
"children":[
"PMID: 32956597"
]
}
]
]
}